Compare DexCom, Inc. (DXCM) vs Mongodb Inc (MDB) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

MongoDB (MDB) trades at $344.67, up 2.1% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beats and robust revenue growth to $2.01B in 2025 highlight operational momentum, though the company remains unprofitable with a net margin of -1.12%. AI-driven demand for database solutions is fueling positive sentiment, as reflected in raised FY2027 guidance.

The outlook is positive given consistent earnings surprises and a consensus price target of $400.39, but risks include persistent losses, high valuation multiples, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.